Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
G1 Therapeutics, Inc. (GTHX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
4
| Velleca Mark A. (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 57,286 shares
@ $1.9986, valued at
$114.5k
Sold 2,714 shares
@ $2.02, valued at
$5.5k
Exercised 57,286 options to buy
@ $0.39, valued at
$22.3k
Exercised 2,714 options to buy
@ $0.3, valued at
$814.2 |
|
| 08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
4
| Perry Andrew (Chief Commercial Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 355 shares
@ $2.4537, valued at
$871.1 |
|
| 07/07/2023 |
4
| MURDOCK TERRY L (COO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 1,361 shares
@ $2.4537, valued at
$3.3k
|
|
| 07/07/2023 |
4
| Malik Rajesh (Chief Medical Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 1,361 shares
@ $2.4537, valued at
$3.3k
|
|
| 07/07/2023 |
4
| Bailey John E. (Jack) Jr. (President and CEO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 2,719 shares
@ $2.4537, valued at
$6.7k
|
|
| 06/16/2023 |
4
| Sharpless Norman (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Flowers Cynthia Louise (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| MUIR GLENN P (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Lee Jacks (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Secor Alicia (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Nicholson Garry A (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 06/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/24/2023 |
3
| Thomas Monica R. (General Counsel) has filed a Form 3 on G1 Therapeutics, Inc. |
| 05/24/2023 |
4
| Thomas Monica R. (General Counsel) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 150,000 options to buy
@ $2.88, valued at
$432k
|
|
| 05/12/2023 |
4
| MURDOCK TERRY L (COO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Avagliano Mark (Chief Business Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Malik Rajesh (Chief Medical Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Umstead John V. (CFO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Perry Andrew (Chief Commercial Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Bailey John E. (Jack) Jr. (President and CEO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 160,000 shares
@ $0 |
|
| 05/03/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/17/2023 |
4
| Umstead John V. (CFO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 100,000 options to buy
@ $3.27, valued at
$327k
|
|
| 03/17/2023 |
3
| Umstead John V. (CFO) has filed a Form 3 on G1 Therapeutics, Inc. |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
|
|
|